Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides
C. Arturo Solares, … , Gordon B. Hughes, Vincent K. Tuohy
C. Arturo Solares, … , Gordon B. Hughes, Vincent K. Tuohy
Published April 15, 2004
Citation Information: J Clin Invest. 2004;113(8):1210-1217. https://doi.org/10.1172/JCI18195.
View: Text | PDF
Article Autoimmunity

Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides

  • Text
  • PDF
Abstract

Autoimmune sensorineural hearing loss (ASNHL) is characterized typically by bilateral, rapidly progressive hearing loss that responds therapeutically to corticosteroid treatment. Despite its name, data implicating autoimmunity in the etiopathogenesis of ASNHL have been limited, and targeted self-antigens have not been identified. In the current study we show that the inner ear–specific proteins cochlin and β-tectorin are capable of targeting experimental autoimmune hearing loss (EAHL) in mice. Five weeks after immunization of SWXJ mice with either Coch 131–150 or β-tectorin 71–90, auditory brainstem responses (ABR) showed significant hearing loss at all frequencies tested. Flow cytometry analysis showed that each peptide selectively activated CD4+ T cells with a proinflammatory Th1-like phenotype. T cell mediation of EAHL was determined by showing significantly increased ABR thresholds 6 weeks after adoptive transfer of peptide-activated CD4+ T cells into naive SWXJ recipients. Immunocytochemical analysis showed that leukocytic infiltration of inner ear tissues coincided with onset of hearing loss. Our study provides a contemporary mouse model for clarifying our understanding of ASNHL and facilitating the development of novel effective treatments for this clinical entity. Moreover, our data provide experimental confirmation that ASNHL may be a T cell–mediated organ-specific autoimmune disorder of the inner ear.

Authors

C. Arturo Solares, Andrea E. Edling, Justin M. Johnson, Moo-Jin Baek, Keiko Hirose, Gordon B. Hughes, Vincent K. Tuohy

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
CD4+ T cells respond to Coch 131–150 and β-tectorin 71–90. LN cells from...
CD4+ T cells respond to Coch 131–150 and β-tectorin 71–90. LN cells from mice primed to (A) Coch 131–150 and (B) β-tectorin 71–90 were stimulated in vitro for 3–4 days with 100 μg/ml peptide, washed repeatedly, and examined by flow cytometry after staining with FITC-conjugated mAb to mouse CD4 or CD8. The gated lymphocyte populations identified by intermediate size (forward scatter) and intermediate granularity (side scatter) consisted of predominantly CD4+ T cells responding to each peptide. The hollow unshifted peak shows superimposed staining with isotype control Ab’s.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts